FDA records dated 11 September show a supplement to abbreviated new drug application ANDA040506, Chartwell RX's generic ethosuximide. Supplements to generic applications usually cover manufacturing, labelling or supplier changes; the record does not say which, and there is no safety communication attached.
Ethosuximide remains a first-line option for childhood absence epilepsy. Nothing here changes how it is prescribed or monitored.
- No change to prescribing or monitoring
- Supply of generic ethosuximide in the US continues through this manufacturer
- Indian availability is unaffected by a US generic supplement
Why it matters
It confirms continued generic supply of a first-line drug for absence epilepsy, and nothing more.
Don't overread it
A supplement to a generic application is not a new indication or a safety finding.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for neurology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free